ASCO 2019 | Tepotinib: advanced non-small cell lung cancer

Paul Paik, MD, of the Memorial Sloan Kettering Cancer Center, New York, NY highlights the key findings from the trial testing tepotinib for patients with METex14 alteration in advanced non-small cell lung cancer. It was found to be well tolerated and there is potential for further development. This interview was recorded at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.